Bluesail Medical Successfully Acquires Swiss TAVR Company NVT AG for RMB 1.39 Billion

Yiou Health, June 9:Bluesail MedicalIn its announcement, the company stated that the acquisition of 100% equity interest in NVT AG (“NVT”), an interventional aortic valve company, for RMB 1.39 billion has been successfully completed. Effective immediately, NVT, a Swiss-based heart valve research and development enterprise, will be formally integrated into Bluesail Medical. According to the announcement, June 8, 2020, was designated as the closing date for this transaction, on which Bluesail Medical and its wholly-owned subsidiary, Bluesail New Valve Technology HK Limited, jointly signed the “Closing Confirmation” with the selling shareholders of NVT AG. NVT’s primary product is Allegra, an implantable device for Transcatheter Aortic Valve Replacement (TAVR), mainly used to treat aortic stenosis. The global TAVR market was valued at USD 4 billion in 2019. Predictions from the Transcatheter Cardiovascular Therapeutics conference indicate that by 2025, the economic value of TAVR will surpass that of coronary stents. With the addition of NVT, Bluesail Medical has officially entered the TAVR sector.